MAFLD/NAFLD biopsy-free scoring systems

Commentary

The current clinical practice is urged to incorporate biopsy-free scoring systems that demonstrate adequate performance metrics for the accurate detection of patients with MAFLD and underlying conditions or those with contraindications of biopsy.

This article presents a thorough review of biopsy-free scoring systems proposed for the diagnosis of MAFLD. It compares the severity of the disease by contrasting the corresponding serum markers, clinical associations, and performance metrics of these biopsy-free scoring systems.